Mitralign Inc.
This article was originally published in Start Up
Executive Summary
Mitralign Inc.'s percutaneous approach to mitral valve repair mimics surgical annuloplasty, the current gold standard treatment for reducing the dilated annulus to a functional size. The company is targeting patients who have both congestive heart failure and mitral valve regurgitation.
You may also be interested in...
NeoChord Inc.
NeoChord wants to enable less invasive mitral valve repair with the NeoChord DS1000 is a tool for implanting artificial chordae tendineae made of suturing material while the heart is still beating.
Evalve, Mitralign Deals: Heart Valves Draw New Device Investors
Over the last few years, interventional heart valve technologies have been among the most popular segments of the cardiovascular device market with venture investors. This popularity has resulted in some VCs concluding that the space has become saturated. While the market may be getting tougher to enter for newcomers, the successful financing rounds recently closed by Evalve and Mitralign show that investors--including new device investors--remain bullish on companies that can demonstrate an effective percutaneous alternative to existing surgical procedures.
In Heart Valves, The End of Watchful Waiting?
Health Research International has just issued a report, "US Opportunities in Heart Valve Disease Management." According to the report, the market for valve replacement and repair products will grow from more than $500 million in 2004 to some $900 million in 2010, with the greatest growth occurring in percutaneous valve products.